Trials / Unknown
UnknownNCT03585426
Vancomycin in the Target Site Treatment of Intracranial Infection
Vancomycin in the Target Site Treatment of Intracranial Infection : a New Strategy for PK/PD Treatment
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the management of complicated multi-organism infections. However,current LC-MS/MS methods briefly describe parameters and the only reported internal standard was sometimes difficult to obtain. In our study,an updated LC-MS/MS method for the quantitative analysis of vancomycin in human serum was developed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vancomycin | Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2018-07-13
- Last updated
- 2018-07-13
Source: ClinicalTrials.gov record NCT03585426. Inclusion in this directory is not an endorsement.